Formycon: Efficacy and safety of the biosimilar ranibizumab FYB201 in comparison to lucentis in patients with neovascular age-related macular degeneration (Columbus-AMD)

Age-related macular degeneration (AMD) is a progressive degenerative disease of the foveal center point (macula). There are two types of AMD: dry (atrophic) and wet (neovascular or exudative). Recent scientific reports suggest that the vascular endothelial growth factor (VEGF) plays a crucial role in the pathophysiology of the wet form of AMD. Hence, one therapeutic approach is the treatment with Ranibizumab (Lucentis®), a VEGF inhibitor. Ranibizumab (FYB201) is a biosimilar of this drug and should work in a similar manner. The objective of this study is therefore to evaluate and compare safety and therapeutic success of the biosimilar Ranibizumab (FYB201) in comparison to the reference product Lucentis in patients with wet AMD.